Revolution Medicines Announces Zoldonrasib Showed Manageable Safety, Tolerability Profile In Two Phase 1/2 Clinical Studies; Objective Response Rate Stood At 82%, Disease Control Rate Was 96%

뉴스 본문을 불러오고 있어요.

Revolution Medicines Announces Zoldonrasib Showed Manageable Safety, Tolerability Profile In Two Phase 1/2 Clinical Studies; Objective Response Rate Stood At 82%, Disease Control Rate Was 96% | 웨이프 WAPE

Revolution Medicines Announces Zoldonrasib Showed Manageable Safety, Tolerability Profile In Two Phase 1/2 Clinical Studies; Objective Response Rate Stood At 82%, Disease Control Rate Was 96%

기사 요약

관련 종목

댓글 —